Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsDenver-Health Medical Plan specialty drug Prior Au…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentDenver-Health-Medical-PlanPolicy H5608_PA25_C

    Prior authorization requirements for specialty drugs

    Customize your policy alerts

    Sign up for Denver-Health-Medical-Plan Policy H5608_PA25_C alerts

    Get alerted when Policy H5608_PA25_C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements, clinical prerequisites, prescriber restrictions, coverage durations, and other PA criteria for multiple specialty pharmacy products for Denver-Health-Medical-Plan Medicare products (Elevate Medicare Choice HMO D‑SNP and Elevate Medicare Select HMO). Affects providers requesting coverage for listed drugs.

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyPrior authorization requirements for specialty drugs
    Policy CodePolicy H5608_PA25_C
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required clinical documentation (e.g., relevant labs, imaging, specialist consultation, and prior therapy trials) per product-specific criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~40+listed products with PA rules in this part
    12 MONTHSmost common coverage duration
    6 MONTHSinitial coverage (many biologics/CGRP)
    24 MONTHSTYMLOS coverage duration
    Specialist consultspecialist prescriber often required

    Coverage Criteria by Product / Indication

    TYMLOS — Initial coverage

    Covered when ALL of the following are met for TYMLOS:

    TYMLOS initial criteria: Patient meets an FDA‑approved indication for TYMLOS (osteoporosis) AND patient has not received a total of 24 months cumulative parathyroid hormone therapycoverage duration 24 MONTHS

    Document that patient has not received a total of 24 months cumulative parathyroid hormone therapy.

    Humira-family and related biologics — Initial and renewal

    Covered when ALL of the following are met for Humira and many related biologics:

    RA initial: Trial of or contraindication to 3 months of one DMARD (if methotrexate tried then trial at ≥20 mg/week or maximally tolerated dose) AND prescribed by or in consultation with a rheumatologistinitial coverage 6 months
    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyPrior authorization requirements for specialty drugs
    Policy CodePolicy H5608_PA25_C
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required clinical documentation (e.g., relevant labs, imaging, specialist consultation, and prior therapy trials) per product-specific criteria.
    SourceLink
    On This Page
    Coverage Criteria by Product / IndicationPrior Authorization, Documentation & Denial RisksProduct Codes, Strengths and IdentifiersClinical Thresholds & Quick ValuesInitial Therapy / Medical Necessity RequirementsRenewal / Continuation RequirementsStep Therapy & Required TrialsQuantity Limits & Course RestrictionsSite of Care & Payment DeterminationBiosimilar References & RequirementsPolicy BackgroundDefinitions and AbbreviationsPolicy Revision History

    Prescribed by or in consultation with a rheumatologist for specified diagnoses

    Psoriasis initial: Psoriasis covering ≥3% BSA or lesions affecting hands/feet/face/scalp/genital area OR prior trial of systemic immunosuppressant or PUVA per policy pathways; AND no concurrent use with another systemic biologic or targeted small moleculeinitial coverage 6 months

    Prescriber specialty restrictions apply

    Renewal: Patient continues to benefit from the medication AND no concurrent use with another systemic biologic or targeted small molecule for specified indicationsrenewal coverage 12 months (HS 12 months)

    Specific renewal criteria vary by indication

    ARIKAYCE — Initial and renewal

    ARIKAYCE coverage and renewal:

    Initial: Prescribed for Mycobacterium avium complex (MAC) lung disease by or in consultation with a pulmonologist or infectious disease specialistinitial coverage 6 months

    All FDA‑approved indications

    Renewal: No positive MAC sputum culture after consecutive negative cultures AND improvement in symptoms; first renewal requires ≥1 negative MAC sputum culture by 6 months; second and subsequent renewals require ≥3 negative MAC sputum cultures by 12 monthsrenewal coverage 6 months

    Documentation of cultures and clinical improvement required

    Oncology targeted agents — Coverage

    Selected oncology agents:

    Oncology targeted agents: Indication is FDA‑approved for the product; coverage duration typically 12 months; where applicable, indication‑specific prerequisites apply (e.g., castrate testosterone documentation for prostate cancer agents)12 MONTHS

    All FDA‑approved indications

    Movement disorder agents — Coverage

    Neurology and movement disorders:

    ONAPGO: Prescribed by or in consultation with a neurologist for Parkinson disease; initial/renewal coverage 12 months; renewal requires improvement in motor symptoms while on therapy12 MONTHS

    All FDA‑approved indications

    KYNMOBI: Patient is ≥18 years and therapy prescribed by or in consultation with a neurologist; initial coverage 6 months with renewal 12 months; renewal requires improvement in motor fluctuations during off episodesinitial 6 months

    All FDA‑approved indications

    Initial Therapy (FASENRA — Asthma initial)

    FASENRA — Asthma (initial): Covered when ALL of the following are met

    FASENRA Asthma Initial Criteria: 1) Blood eosinophils ≥150 cells/mcL within past 12 months; 2) Prescribed by or in consultation with an allergy or pulmonary specialist; 3) Concurrent therapy with a medium/high‑dose or maximally tolerated inhaled corticosteroid plus one other maintenance medication; 4) History of exacerbation (systemic steroid burst ≥3 days in past 12 months, or hospitalization/ER visit) OR poor symptom control evidenced by ≥3 features within past 4 weeks; 5) No concurrent use with XOLAIR, DUPIXENT, TEZSPIRE, or other anti‑IL5 biologics for asthma

    Continuation Therapy (FASENRA — Asthma renewal)

    FASENRA — Asthma (renewal): Covered when ALL of the following are met

    FASENRA Asthma Renewal Criteria: 1) No concurrent use with XOLAIR, DUPIXENT, TEZSPIRE, or other anti‑IL5 biologics for asthma; 2) Continued use of inhaled corticosteroid and one other maintenance medication; 3) Clinical response evidenced by reduction in exacerbations, decreased rescue medication use, increase in percent predicted FEV1 from baseline, or reduction in severity/frequency of asthma‑related symptoms.

    Psoriasis / PSA Initial Therapy

    Psoriasis / Psoriatic Arthritis: Initial coverage requirements

    Mild Psoriasis Initial: Trial of or contraindication to one conventional systemic therapy (e.g., methotrexate, acitretin, cyclosporine) OR one conventional topical therapy or phototherapy (PUVA/UVB/topical corticosteroids) as appropriate for mild PSO

    Document BSA/SPGA/PASI where applicable

    Moderate to Severe Psoriasis Initial: Either (A) ≥3 month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA, (B) contraindication/intolerance to both, or (C) switching from a different biologic/PDE‑4/JAK for same indication; AND no concurrent use with another systemic biologic or targeted small molecule for moderate‑severe PSO

    Prescriber specialty consultation recommended

    HAE Initial Therapy (HAEGARDA)

    HAEGARDA — Hereditary angioedema (initial): Covered when ALL of the following are met

    HAE Diagnostic Criteria: Diagnosis confirmed by complement testing: C1‑INH protein level OR C4 protein level OR C1‑INH functional level OR C1q

    Prescriber must be or consult hematologist, immunologist, allergist, or pulmonologist

    HAE Prescriber: Prescribed by or in consultation with a hematologist, immunologist, allergist, or pulmonologist AND patient is not on concurrent alternative prophylactic agent for HAE attacks

    Initial/renewal coverage 12 months; renewal requires reduction in attack frequency/severity

    CML Mutation-guided Therapy (SCEMBLIX / BOSULIF)

    SCEMBLIX / BOSULIF for Ph+ CML: Pre-initiation requirements

    Mutational analysis requirement: Mutational analysis (BCR‑ABL1 mutation profile) prior to initiation when indicated (e.g., previously treated Ph+ CML or T315I mutation consideration) per NCCN‑based recommendations

    Appropriate mutation testing must be documented

    PAH Initial Therapy (Bosentan)

    Bosentan — PAH initial: Covered when ALL of the following are met

    PAH Diagnostic Confirmation: Diagnosis confirmed by right heart catheterization with mean PAP >20 mmHg AND PCWP ≤15 mmHg AND PVR >2 Wood units; prescribed by or in consultation with a cardiologist or pulmonologist; no ALT/AST >3x ULN or bilirubin increase ≥2x ULN; no concurrent use with cyclosporine A or glyburide

    Coverage duration initial/renewal 12 months

    General and product-specific PA criteria

    Coverage is generally provided when the product is used for FDA‑approved indications and when drug-specific clinical prerequisites are met:

    General FDA-approved indication requirement: Indication must be an FDA‑approved indication for the product

    Present for most listed products

    Coverage duration: Most products: 12 months initial/renewal unless otherwise specified

    Typical duration noted across products

    Prescriber specialty restrictions where specified: Certain agents require prescription by or in consultation with specified specialists (e.g., HAE by hematologist/immunologist/allergist/pulmonologist; PAH by cardiologist/pulmonologist)

    Prescriber specialty required for some agents

    Step therapy: For many autoimmune and dermatologic biologics, initial authorization requires trial of or contraindication to specified preferred agents (often two preferred agents; exceptions apply)

    See product‑specific step requirements

    Laboratory/genetic confirmation when required: Some drugs require specific lab or genetic confirmation prior to initiation (e.g., HAE complement testing; deferasirox ferritin/LIC thresholds; mutational analysis for Ph+ CML)

    Document required tests/results

    Pharmacy/Part B flags: Some products include Part B prerequisite notes or payment determination statements; verify Part B vs Part D applicability

    Payment determination may be required for certain agents

    Dupilumab Initial and Renewal Criteria

    Covered when ALL of the following indication-specific requirements are met for dupilumab:

    Dupilumab initial criteria general: Indication is FDA‑approved and objective criteria per indication are documented (e.g., blood eosinophils 150–1500 for eosinophilic asthma; EoE confirmed by EGD with biopsy; AD covering ≥10% BSA or affecting special areas)varies by indication

    Prescriber must be specialist or in consultation per indication

    Dupilumab indication-specific required trials: Initial: AD requires trial of or contraindication to one topical agent (steroid, calcineurin inhibitor, PDE4 inhibitor, or JAK inhibitor); Asthma requires concurrent ICS+maintenance and prior exacerbation/poor control criteria; CRSwNP requires 56‑day topical nasal steroid trial; PN requires chronic pruritus ≥6 weeks with specified featuressee node text

    No concurrent use with certain other biologics or targeted small molecules as specified

    Dupilumab renewal criteria: Renewal: evidence of clinical improvement while on therapy per indication (e.g., reduced exacerbations or improved FEV1 for asthma; symptom improvement for AD/CRSwNP/EOE/PN)clinical improvement metrics vary by indication

    Coverage durations vary by indication (initial/renewal 6–12/12 months per indication)

    Droxidopa (NOH) Criteria

    Covered when ALL of the following are met for NOH:

    Droxidopa initial criteria: Baseline blood pressure readings sitting and within 3 minutes of standing documented AND orthostatic drop ≥20 mmHg systolic OR ≥10 mmHg diastolic within 3 minutes AND prescribed by or in consultation with a neurologist or cardiologist>=20 mmHg systolic or >=10 mmHg diastolic drop

    Initial coverage 3 months; renewal 12 months with continued benefit documented

    Eltrombopag / Alvaiz Criteria

    Covered when ALL of the following are met for persistent or chronic immune thrombocytopenia (ITP):

    Eltrombopag/Alvaiz ITP initial criteria: Platelet count <30 x10^9/L OR platelet count <50 x10^9/L with prior bleeding event; trial of or contraindication to one corticosteroid or IVIG or insufficient response to splenectomy; prescribed by or in consultation with a hematologist or immunologist; no concurrent use with other TPO‑RAsplatelet count thresholds as stated

    Initial coverage 6 months; renewal 12 months with improvement in platelet count or reduced bleeding events

    Eltrombopag formulation trial requirement: Approval for oral suspension packets requires trial of a formulary tablet version or inability to tolerate tablet formulationN/A

    Applies to all indications

    Elagolix (Orilissa) Criteria

    Covered when ALL of the following are met for moderate-to-severe pain associated with endometriosis:

    Elagolix initial criteria: Diagnosis confirmed via surgical/direct visualization or histopathology within past 10 years; patient ≥18 years; prescribed by or in consultation with an OB/GYN; trial of or contraindication to an NSAID and a progestin-containing preparation; no concurrent use with another GnRH‑modulating agentage >=18; diagnosis confirmation within 10 years

    Initial duration 6 months; renewal 12 months with improvement in pain

    Retacrit (EPO) Criteria

    Covered when hemoglobin thresholds appropriate to indication are met:

    Retacrit initial/renewal criteria by indication: For CKD, anemia related to zidovudine, or chemotherapy: hemoglobin <10 g/dL; for elective non‑cardiac, non‑vascular surgery: hemoglobin <13 g/dL. Renewal requires maintained thresholds or appropriate dose adjustments per guidanceHb <10 g/dL (most indications); surgery <13 g/dL

    Initial/renewal durations vary by indication

    Diclofenac Topical Criteria

    Covered when ALL of the following are met for osteoarthritis of the knee:

    Diclofenac topical criteria: Trial of or contraindication to a formulary version of diclofenac sodium 1% topical gel AND a formulary version of diclofenac sodium 1.5% topical drops prior to approval for diclofenac sodium topical solution in metered‑dose pump

    Coverage duration 6 months

    Rozlytrek oral pellets Criteria

    Covered when BOTH of the following are met for Rozlytrek oral pellets:

    Rozlytrek pellet formulation criteria: Patient has an indication consistent with product labeling AND trial of or contraindication to Rozlytrek capsules made into an oral suspension and documentation of difficulty or inability to swallow capsules

    Coverage duration 12 months

    Xtandi Criteria

    Covered when ALL of the following are met for prostate cancer indications:

    Xtandi eligibility criteria: Documentation of castrate state via bilateral orchiectomy OR testosterone <50 ng/dL OR concurrent use with a GnRH analog; for NMCRPC high risk: rapidly increasing PSA (PSA doubling time ≤9 months) as applicable; coverage duration initial 12 months and renewals require continued castrate documentationtestosterone <50 ng/dL or orchiectomy; PSA doubling time <=9 months for NMCRPC high risk

    All FDA‑approved indications considered

    Balversa — Initial Therapy

    Balversa

    Balversa initial: Indication is FDA‑approved for Balversa; coverage duration 12 months

    Prescriber and other product‑specific requirements per labeling

    Aimovig/Ajovy — Initial and Renewal Criteria (CGRP inhibitors)

    CGRP inhibitors for migraine prevention

    Initial authorization: No concurrent use with other CGRP inhibitors for migraine prevention AND initial coverage duration 6 months

    Renewal 12 months with documented reduction in migraine/headache frequency, severity, or duration

    Renewal requires documented reduction in migraine or headache frequency, severity, or duration on therapy

    Prescriber specialty as appropriate

    VOWST — Initial and Repeat Course Criteria

    VOWST for recurrent C. difficile infection

    Initial course: Patient has not previously received VOWST AND completion of antibiotic treatment for recurrent CDI (at least 3 CDI episodes) documented

    Coverage duration 30 days

    Repeat course: If previously received VOWST, coverage requires documented treatment failure (CDI diarrhea within 8 weeks of first dose plus positive stool test) AND patient has not received more than one prior VOWST course meeting duration/timeframe criteria

    Repeat‑course limits and timing apply

    Kerendia — Initial Criteria

    Kerendia (finerenone) criteria

    HF initial: NYHA class II–IV AND LVEF ≥40% not due to specified causes AND prescribed by or in consultation with a cardiologist AND no concurrent use with another mineralocorticoid receptor antagonistLVEF >= 40%

    Coverage durations generally 12 months

    Biologics — Initial and Renewal Criteria

    Biologic therapy requirements for psoriasis, psoriatic arthritis, RA, AS, UC, CD

    Psoriasis initial: Plaque psoriasis initial: psoriasis covering ≥3% BSA or involvement of sensitive areas AND trial of or contraindication to listed systemic immunosuppressants or PUVA OR switching from another biologic/PDE‑4/JAK; no concurrent use with another systemic biologic or targeted small molecule>=3% BSA

    Initial coverage commonly 6 months; renewal 12 months with continued benefit required

    Rheumatologic indications: For RA/PSA/AS: trial of or contraindication to specified conventional therapy per indication (e.g., 3 months of a DMARD for RA; NSAID trial for AS); no concurrent systemic biologic or targeted small molecule; specialist prescribing where specified

    Initial commonly 6 months; renewal 12 months

    Fintepla — Initial and Renewal Criteria

    Fintepla (fenfluramine) criteria for LGS/Dravet

    Fintepla initial: For LGS: trial of or contraindication to two listed antiepileptic medications (e.g., rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam) AND prescribed by or in consultation with a neurologist; initial/renewal coverage 12 monthstrial of 2 agents

    Applies per product labeling

    Morphine concentrate — Criteria

    Morphine concentrate criteria

    Opioid tolerant use: Patient is opioid‑tolerant (defined by specified prior opioid use equivalents) AND has difficulty swallowing tablets/capsules or is enrolled in hospice/palliative/end‑of‑life careopioid‑tolerant definition

    Coverage duration 12 months for opioid‑tolerant; lifetime for hospice/palliative care

    Imatinib/Imkeldi — Duration and Special Criteria

    Imatinib / Imkeldi duration rules

    Adjuvant GIST: Adjuvant gastrointestinal stromal tumor (GIST) treatment: coverage duration 36 months; all other diagnoses: 12 months; IMKELDI may be approved when patient unable to swallow generic imatinib tablets36 months for adjuvant GIST

    For Ph+ CML ensure patient has not received prior TKI therapy

    Icatibant — Criteria

    Icatibant for hereditary angioedema (HAE)

    HAE initial: Diagnosis confirmed by complement testing AND prescribed by or in consultation with an allergist/immunologist/hematologist AND no concurrent use with other medications for treatment of acute HAE attacks

    Coverage duration 12 months

    HAE — Initial/renewal criteria (general HAE products)

    Covered when ALL of the following are met for HAE products:

    HAE coverage criteria: Hereditary angioedema diagnosis confirmed by complement testing; prescribed by or in consultation with an allergist, immunologist, or hematologist; no concurrent use with other medications for treatment of acute HAE attacks; coverage duration 12 months

    Document complement testing results

    Imatinib / IMKELDI — Initial/renewal

    Covered when ALL of the following are met for imatinib/IMKELDI:

    Imatinib coverage criteria: Indication is FDA‑approved; adjuvant GIST coverage duration 36 months, other diagnoses 12 months; for Philadelphia chromosome‑positive CML patient has not received previous treatment with another TKI; IMKELDI approved if unable to swallow generic imatinib tablets

    Document indication and prior TKI exposure

    Biologics (infliximab and others) — Initial/renewal

    Covered when ALL of the following are met for infliximab and similar biologics:

    Biologic initial coverage: Initial coverage: disease‑specific prerequisites (e.g., PSO ≥3% BSA or sensitive‑site involvement), prescriber specialty per indication, initial typically 6 months with renewal 12 months; trial of or contraindication to two preferred agents required for certain diagnoses; no concurrent systemic biologic or targeted small molecule therapy; payment determination when applicable

    Document prior trials and BSA/clinical measures as applicable

    Insulin administration supplies coverage limitation

    General coverage notes for insulin-related supplies

    Part D limitation: Items listed (insulin syringes, pen needles, alcohol prep pads, sharps containers) are ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN

    Coverage duration LIFETIME for these supplies when applicable

    Actimmune initial and renewal criteria

    Actimmune (interferon gamma‑1b) coverage criteria

    Initial criteria for CGD and SMO: Prescribed by or in consultation with appropriate specialist (hematologist/infectious disease/immunologist for CGD; endocrinologist/hematologist for SMO); initial coverage 6 months; renewal 12 months with demonstrated clinical benefit and patient has not received hematopoietic cell transplant

    Specialist prescriber required

    Kalydeco initial and renewal criteria

    Kalydeco (ivacaftor) coverage criteria

    CF diagnostic requirement: Confirmed CFTR mutation acceptable for the therapy AND prescribed by or in consultation with a pulmonologist or cystic fibrosis expert

    Initial coverage 12 months; renewal lifetime contingent on clinical improvement

    Lanreotide / Somatuline criteria

    Lanreotide / Somatuline coverage criteria

    Acromegaly requirement: Prescribed by or in consultation with an endocrinologist AND trial of or contraindication to one generic octreotide injection prior to lanreotide initiation

    Initial coverage acromegaly 3 months; renewal 12 months with IGF‑1/symptom improvement

    Yervoy durations and renewal condition

    Yervoy (ipilimumab) coverage durations

    Indication-specific durations: Coverage durations vary by indication (e.g., unresectable/metastatic melanoma 4 months; RCC/CRC/HCC 3 months; most others 12 months); renewal conditions vary (e.g., adjuvant cutaneous melanoma renewal requires no evidence of disease recurrence)

    Payment determination may apply

    Cystic fibrosis (CF) products coverage criteria

    Cystic fibrosis (CF) products (e.g., ORKAMBI and other CF modulators) are covered when ALL of the following are met

    CF initial criteria: Confirmed CFTR mutation acceptable for the treatment AND prescribed by or in consultation with a pulmonologist or CF expert; product‑specific genotype eligibility must be met

    Initial duration 6–12 months depending on product; renewal requires clinical improvement

    NUCALA (mepolizumab) criteria

    NUCALA coverage criteria differ by indication and require ALL of the following for initial approval

    Asthma indication: Blood eosinophils ≥150 cells/mcL within past 12 months; prescribed by or in consultation with pulmonary or allergy specialist; background therapy with medium/high‑dose ICS plus at least one other maintenance med; history of exacerbation OR poor control per policy definitions; no concurrent use with XOLAIR, DUPIXENT, TEZSPIRE, or other anti‑IL5 biologics for asthmablood eosinophils >=150 cells/mcL

    Initial duration 12 months for asthma; CRSwNP initial 6 months; renewal requires clinical benefit

    CRSwNP indication: 56‑day trial of topical nasal corticosteroid; prescribed by ENT/allergist/immunologist; no concurrent systemic biologic or targeted small molecule for autoimmune indication

    Initial 6 months; renewal requires clinical benefit

    Eosinophilic COPD indication: Used in combination with LAMA/LABA/ICS; prescribed by pulmonologist; no concurrent use with another systemic biologic or targeted small molecule for same indication

    Renewal requires clinical response (reduced exacerbations or ≥5% increase in FEV1)

    OPSUMIT (PAH) criteria

    OPSUMIT (macitentan) for pulmonary arterial hypertension is covered when ALL of the following are met

    PAH diagnostic criteria: Diagnosis confirmed by right heart catheterization with mean PAP >20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units; prescribed by or in consultation with a cardiologist or pulmonologistmean PAP >20 mmHg; PCWP <=15 mmHg; PVR >2 Wood units

    Initial and renewal duration 12 months

    Somatostatin analogs for acromegaly

    Lanreotide/Somatuline for acromegaly is covered when ALL of the following are met

    Acromegaly initial criteria: Prescribed by or in consultation with an endocrinologist AND trial of or contraindication to one generic octreotide injection prior to lanreotide initiation

    Initial coverage 3 months; renewal 12 months based on IGF‑1 normalization/clinical improvement

    Endometriosis (GnRH agents)

    GnRH‑modulating agents for endometriosis are covered when ALL of the following are met

    Endometriosis initial criteria: Diagnosis confirmed via surgical/direct visualization or histopathology within past 10 years; prescribed by or in consultation with an OB/GYN; trial of or contraindication to NSAID and a progestin‑containing preparation; not exceeded lifetime treatment limits and no concurrent use with another GnRH‑modulating agentdiagnosis confirmation within 10 years; lifetime treatment <=12 months

    Initial/renewal duration 6 months; renewal requires pain improvement and add‑back therapy

    CPP (pediatric leuprolide) criteria

    Central precocious puberty (CPP) coverage criteria for pediatric leuprolide products

    CPP initial criteria: Diagnostic labs at baseline (FSH/LH thresholds per sex) AND onset age thresholds and Tanner staging criteria met; prescribed by or in consultation with an endocrinologistFSH/LH thresholds as specified; age thresholds

    Initial/renewal coverage 12 months; renewal requires Tanner staging stabilization/regression

    Glutamine (sickle cell) criteria

    Glutamine for sickle cell disease (SCD)

    SCD initial criteria: Adults (≥18): at least 2 sickle cell crises in past year OR symptoms interfering with activities of daily living OR history/recurrent acute chest syndrome; ages 5–17 approved without additional criteria; prescribed by or in consultation with a hematologist>=2 crises in past year for adults

    Initial 12 months; renewal requires maintained or reduced acute complications

    OFEV coverage criteria

    OFEV (nintedanib) coverage rules — initial and renewal criteria by indication

    Initial IPF: HRCT demonstrating UIP pattern (or surgical lung biopsy + HRCT) AND baseline FVC ≥50% predicted AND exclusion of other known causes of ILD; prescribed by or in consultation with a pulmonologistFVC >=50%

    Initial coverage IPF 12 months; renewal requires meaningful improvement or maintenance in annual rate of decline

    Initial SSC-ILD: At least 10% fibrosis on chest HRCT AND baseline FVC ≥40% predicted AND exclusion of other known causes of ILD AND trial of or contraindication to preferred agent (Actemra SQ)FVC >=40%

    Initial coverage SSC‑ILD 6 months; prescriber pulmonologist or rheumatologist

    Initial PF-ILD: At least 10% fibrosis on chest HRCT AND baseline FVC ≥45% predicted AND progression/worsening of lung function or imaging despite treatment; prescribed by pulmonologyFVC >=45%

    Initial coverage PF‑ILD 12 months; renewal requires clinical benefit

    XOLAIR coverage criteria

    XOLAIR coverage rules by indication

    Initial CSU: Trial of and maintained on, or contraindication to, a second‑generation H1 antihistamine AND still experiences hives or angioedema most days for at least 6 weeks; prescriber allergist/dermatologist/immunologist6 weeks

    Initial coverage typically 6 months; renewal 12 months

    Initial CRSwNP: 56‑day trial of one topical nasal corticosteroid AND trial of or contraindication to one preferred agent (e.g., NUCALA, DUPIXENT) AND no concurrent systemic biologic/targeted small molecule for autoimmune indication; prescriber ENT/allergist/immunologist56 days

    Initial coverage 6 months; renewal requires clinical benefit

    Initial Asthma: Concurrent therapy with medium/high‑dose or maximally tolerated ICS plus at least one other maintenance med AND exacerbation history or poor control per policy criteria AND no concurrent use with Dupixent, Tezspire, or anti‑IL5 biologics for asthma; prescriber allergy/pulmonary specialistexacerbation history or symptom control criteria

    Initial coverage 12 months

    Initial Food Allergy: Specific IgE ≥6 kUA/L to at least one food OR positive skin prick OR positive medically supervised oral food challenge AND concurrent active prescription for epinephrine auto‑injector AND no concurrent peanut‑specific immunotherapy; prescriber allergist/immunologistspecific IgE >=6 kUA/L

    Initial coverage 12 months; renewal 24 months for food allergy

    Orfadin coverage criteria

    ORFADIN (nitisinone) hereditary tyrosinemia type 1 rules

    Initial HT-1: Diagnosis confirmed by elevated urinary or plasma succinylacetone OR FAH gene mutation AND prescribed by or in consultation with a specialist in inherited metabolic diseases; trial of or contraindication to preferred nitisinone tablets/capsules if requesting suspension formelevated succinylacetone or FAH mutation

    Initial coverage 6 months; renewal requires decreased succinylacetone from baseline

    Renewal HT-1: Urinary or plasma succinylacetone levels have decreased from baseline while on treatment with nitisinonedecrease in succinylacetone

    Renewal coverage 12 months

    PARP inhibitor constraints (LYNPARZA, ZEJULA)

    LYNPARZA and ZEJULA noted usage constraints

    PARP inhibitors recurrent ovarian: For recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer ensure monotherapy use; ZEJULA must be started no later than 8 weeks after most recent platinum‑containing regimen. For LYNPARZA in mCRPC ensure prior orchiectomy or castrate testosterone (<50 ng/dL) or concurrent GnRH analog useZEJULA within 8 weeks of platinum regimen; testosterone <50 ng/dL for mCRPC

    Coverage durations generally 12 months

    Prescriber and trial requirements (general)

    Drugs with prescriber specialty or trial requirements

    Lunsumio for R/R FL: Initial duration 6 months; renewal 7 months; renewal requires partial response and not previously received >17 cycles; payment determination may applyresponse and cycle limit

    Prescriber restrictions per product

    Lybalvi for schizophrenia/bipolar I: Prescribed by or in consultation with a psychiatrist AND trial of or contraindication to specified formulary antipsychotics or circumstances of high weight‑gain risktrial of formulary agents

    Coverage duration 12 months

    Hypocalcemia secondary to hypoparathyroidism criteria

    Hyopcalcemia secondary to hypoparathyroidism — covered when ALL of the following are met

    Hypoparathyroidism hypocalcemia criteria: Prescribed by or in consultation with an endocrinologist AND trial of or contraindication to calcitriol AND hypoparathyroidism is not due to a calcium sensing receptor (CSR) mutation AND not acute post‑surgical hypoparathyroidism

    Coverage duration 12 months

    Cushing disease (SIGNIFOR) initial approval criteria

    Cushing disease (SIGNIFOR) — initial approval criteria

    SIGNIFOR initial: Prescribed by or in consultation with an endocrinologist

    Initial coverage 6 months; renewal 12 months with evidence of continued improvement and tolerability

    Asthma (CINQAIR) criteria

    Asthma (CINQAIR) — covered when ALL of the following are met

    CINQAIR initial: Blood eosinophils ≥150 cells/mcL within past 12 months; prescribed by or in consultation with an allergy or pulmonary specialist; concurrent therapy with medium/high‑dose ICS plus another maintenance med; exacerbation history OR poor control criteria met; trial of or contraindication to two preferred agents (FASENRA, NUCALA, DUPIXENT); no concurrent use with XOLAIR, DUPIXENT, TEZSPIRE, or other anti‑IL5 biologics for asthma

    Initial/renewal 12 months; renewal requires continued ICS+maintenance and clinical response

    Idiopathic pulmonary fibrosis (pirfenidone)

    Idiopathic pulmonary fibrosis (pirfenidone) — covered when ALL of the following are met

    IPF initial: UIP pattern on HRCT alone OR surgical lung biopsy plus HRCT AND predicted FVC ≥50% at baseline AND prescribed by or in consultation with a pulmonologist AND does not have other known causes of interstitial lung disease

    Initial/renewal 12 months; renewal requires clinical meaningful improvement or maintenance in annual rate of decline

    PAH / CTEPH (ADEMPAS)

    Pulmonary arterial hypertension / CTEPH (ADEMPAS) — covered when ALL of the following are met

    ADEMPAS initial: Diagnosis confirmed by right heart catheterization with mean PAP >20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units; for CTEPH: WHO FC II–IV and not a candidate for surgery or persistent/recurrent disease after surgery; prescribed by or in consultation with a cardiologist or pulmonologist; no concurrent use with nitrates, nitric oxide donors, PDE inhibitors, or non‑specific PDE inhibitors

    Initial/renewal 12 months; strict concurrent therapy exclusions

    Penicillamine—Cystinuria / Wilson disease / RA

    Penicillamine — covered when criteria vary by indication

    Penicillamine indication-specific: Cystinuria: nephrolithiasis plus stone analysis showing cystine OR hexagonal cystine crystals OR family history with positive cyanide‑nitroprusside screening; Wilson disease: Leipzig score ≥4 and hepatologist/gastroenterologist involvement; RA: no renal insufficiency and trial of or contraindication to 3 months of one DMARD (methotrexate trial ≥20 mg/week if used)

    Coverage initial 12 months; renewal varies by indication

    PAH initial coverage criteria

    Covered when ALL of the following are met for PAH (initial):

    PAH hemodynamic confirmation: Right heart catheterization showing mean PAP >20 mmHg AND PCWP ≤15 mmHg AND PVR >2 Wood units (adult); pediatric ages 1–17: PVR ≥3 Wood unitssee thresholds

    Document RHC values

    Prescriber requirement: Prescribed by or in consultation with a cardiologist or pulmonologist

    Specialist involvement required

    Concurrent medication exclusions: No concurrent use with nitrates, nitric oxide donors, PDE inhibitors, or non‑specific PDE inhibitors; some agents also exclude concurrent guanylate cyclase stimulators or ED agents

    Concurrent therapy exclusions must be documented

    CTEPH initial coverage criteria

    Covered when ALL of the following are met for CTEPH (initial):

    CTEPH diagnostic context: Persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) with WHO functional class II–IV symptoms

    Not a candidate for surgery or inoperable/persistent/recurrent disease after surgery

    Surgical candidacy: Not a candidate for surgery OR inoperable OR persistent/recurrent disease after surgical treatment

    Document surgical evaluation

    Concurrent medication exclusions: No concurrent use with nitrates, nitric oxide donors, PDE inhibitors, or non‑specific PDE inhibitors

    Concurrent therapy exclusions apply

    Uptravi initial criteria

    Initial coverage for Uptravi requires:

    Prior trials or contraindications: Trial of or contraindication to two agents from different drug classes (formulary oral endothelin receptor antagonist, formulary oral phosphodiesterase‑5 inhibitor, formulary oral cGMP stimulator) OR documentation of intolerance/contraindication

    Step‑therapy requirement documented

    Plaque psoriasis initial criteria

    Covered when ALL of the following are met for plaque psoriasis initial therapy:

    Prior therapy options: At least one of: ≥3 month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) OR PUVA phototherapy; OR documented contraindication/intolerance to both; OR switching from a different biologic/PDE‑4/JAK for same indication

    Also require no concurrent systemic biologic/targeted small molecule

    Concurrent therapy exclusion: No concurrent use with another systemic biologic or targeted small molecule for the same indication

    Document absence of concurrent biologic/TSM

    HCV direct-acting antivirals criteria

    Covered when ALL of the following are met for HCV agents:

    Lab requirement: HCV RNA level within the past 6 months documentedHCV RNA within 6 months

    Apply AASLD/IDSA guidance

    Guideline adherence: Therapy selection and duration applied consistent with current AASLD/IDSA guidance

    Document regimen and contraindicated interactions checked

    Drug interaction exclusions: Not concurrently taking listed contraindicated medications (amiodarone, carbamazepine, phenytoin, rifampin, certain HIV regimens, other specified agents); verify absence of moderate/severe hepatic impairment for some agents

    Document medication reconciliation and hepatic function where applicable

    VOSEVI — Initial Therapy

    VOSEVI coverage when ALL of the following are met

    VOSEVI initial coverage criteria: Documentation of HCV RNA within past 6 months AND not concurrently taking listed interacting medications; if decompensated cirrhosis present, concurrent ribavirin required unless ribavirin‑ineligible

    Follow AASLD/IDSA guidance

    NORDITROPIN FLEXPRO — Initial Therapy (HCV RNA requirement noted)

    NORDITROPIN FLEXPRO coverage when ALL of the following are met

    NORDITROPIN FLEXPRO initial coverage criteria: Indication‑specific documentation per growth hormone product requirements AND HCV RNA within past 6 months where applicable; exclude use in moderate/severe hepatic impairment (Child‑Pugh B or C) where notedHCV RNA within 6 months where applicable

    Prescribed by or in consultation with an endocrinologist for most indications

    Growth hormone products — Initial and Renewal

    Growth hormone products coverage when ALL of the following are met

    Pediatric growth hormone indications: Indication‑specific documentation (pediatric GHD, ISS, SGA, Turner, Noonan): height ≥2 SD below mean or syndrome criteria; open epiphyses confirmed by wrist/hand radiograph; prescribed by or in consultation with an endocrinologist

    Renewal requires evidence of improvement and open epiphyses for pediatric indications

    PAH agents — Initial Therapy

    Pulmonary arterial hypertension (PAH) agent coverage when ALL of the following are met

    PAH diagnostic confirmation: Diagnosis confirmed by right heart catheterization showing mean PAP >20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units; prescribed by or in consultation with cardiology or pulmonology AND patient on background PAH therapy for at least 3 months with at least two agents from different classes OR has contraindication/intolerance

    Coverage duration typically 12 months

    Actemra — Initial and Renewal

    Actemra coverage when ALL of the following are met

    Actemra RA/PJIA/SJIA/GCA initial criteria: Prescribed by or in consultation with a rheumatologist (and other specialists for SJIA); RA requires trial of or contraindication to two preferred agents; PJIA: trial of or contraindication to two preferred agents and no concurrent systemic biologic/targeted small molecule; renewal requires continued benefit and no concurrent systemic biologic for pediatric indications

    Initial durations vary by indication (initial often 6 months; renewal 12 months)

    Testosterone products — Initial and Renewal

    Testosterone therapies coverage when ALL of the following are met

    Male hypogonadism confirmation: At least two total serum testosterone levels <300 ng/dL on separate occasions OR free testosterone <5 ng/dL; for age ≥40 PSA evaluated prior to initiation and at renewal; coverage duration typically 12 months

    Renewal requires improved symptoms and tolerance

    ACTEMRA / TYENNE Coverage

    ACTEMRA / TYENNE (tocilizumab and biosimilars) — covered when meeting indication‑ and prescriber‑specific requirements

    ACTEMRA initial approval conditions: Patient has an FDA‑approved indication AND initial prescriber is within required specialty per indication (e.g., rheumatologist for RA/PJIA; rheumatologist/dermatologist/immunologist for SJIA)

    See indication‑specific durations (initial often 6 months)

    Step therapy for RA/PJIA: RA: trial of or contraindication to two preferred agents (ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA). PJIA: trial of or contraindication to two preferred agents and no concurrent systemic biologic/TSM

    Renewal requires continued benefit

    ACTEMRA exclusion: Use for hospitalized adults with COVID‑19 is excluded

    Explicit exclusion applies

    XELJANZ Coverage

    XELJANZ / XELJANZ XR — covered when indication‑specific prerequisites and step therapy are met

    Prescriber requirement: Initial prescription by or in consultation with specified specialist depending on indication (e.g., rheumatologist for RA; gastroenterologist for UC)

    Initial authorization 6 months; renewal 12 months

    Step therapy/DMARD trial: RA: trial of or contraindication to 3 months of one DMARD; if methotrexate tried, dose ≥20 mg/week or maximally tolerated dose required; restrictions on concurrent use with other systemic biologics/TSM per indication

    Document DMARD trial or contraindication

    UBRELVY Coverage

    UBRELVY (ubrogepant) — acute migraine agent with triptan trial requirement and renewal PRO measures

    Initial approval: Acute migraine: trial of or contraindication to one triptan is required AND no concurrent use with other CGRP inhibitors for acute migraine treatment

    Initial 6 months; renewal 12 months with patient‑reported improvement or consistent efficacy

    Renewal requires no concurrent CGRP inhibitors AND either patient‑reported improvement on validated outcome OR consistent efficacy across majority of attacks

    Document PROs or consistent effectiveness

    RINVOQ Coverage

    RINVOQ (upadacitinib) — covered when indication‑specific clinical criteria, specialist prescribing, and step therapy are satisfied

    NR-axSpA objective criteria: NR‑axSpA: objective inflammatory evidence (elevated CRP OR sacroiliitis on MRI)

    Prescriber: rheumatologist

    Atopic dermatitis criteria: AD covering ≥10% BSA or involving special areas; trial of or contraindication to topical steroid, topical calcineurin inhibitor, topical PDE4 inhibitor, or topical JAK inhibitor required; no concurrent systemic biologics or JAK inhibitors≥10% BSA or special areas

    Prescriber dermatologist/allergist/immunologist

    Other indications and step therapy: RA: trial of or contraindication to 3 months of one DMARD (methotrexate criteria apply); AS/PSA/UC/CD: additional trials and prohibitions on concurrent systemic biologic/TSM per policy

    Initial 6 months; renewal 12 months with continued benefit

    GCA for STELARA note: For giant cell arteritis with STELARA: patient must have completed, started, or will soon start a tapering course of glucocorticoids

    Document steroid taper

    tolvaptan (ADPKD) Coverage

    Tolcapts/ tolvaptan for ADPKD — covered when diagnostic and specialist prerequisites met

    Diagnostic confirmation: Confirmed polycystic kidney disease via CT, MRI, or ultrasound AND prescribed by or in consultation with a nephrologist; patient must not have ESRD (not on dialysis)

    Initial 6 months; renewal 12 months; renewal requires not progressed to ESRD/dialysis

    General initial and renewal criteria (multiple products)

    Covered when the indication‑specific prerequisites and discontinuation/renewal conditions below are met

    General concurrent therapy prohibition: No concurrent use with another systemic biologic or targeted small molecule (e.g., JAK inhibitor, PDE‑4 inhibitor) for the same indication (applies to PSO, PSA, CD, UC, AS, NR‑AXSPA, PJIA)none

    Applies to many product entries

    Psoriasis initial requirements: At least one of: (A) ≥3 month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA; (B) contraindication/intolerance to both; (C) switching from another biologic/PDE‑4/JAK for same indicationnone

    Applies to PSO entries

    RA initial requirements: Trial of or contraindication to 3 months of one DMARD; if methotrexate tried, trial must be at dose ≥20 mg/week or maximally tolerated dosenone

    Applies to RA entries

    Atopic dermatitis initial requirements: For AD: intractable pruritus or significant skin disease AND trial of or contraindication to topical corticosteroid/calcineurin inhibitor/PDE4/JAK topical; no concurrent systemic biologics or other JAK inhibitorsnone

    Applies to AD entries

    Giant cell arteritis (GCA): Patient has completed, started, or will soon start a tapering course of glucocorticoidsnone

    GCA prerequisite

    Renewal criteria common elements: Renewal requires continued benefit from medication (improvement or maintained effect) AND no concurrent use with another systemic biologic or targeted small molecule for the indicationnone

    Applies to many products

    Product-specific criteria

    Product-specific requirements

    PSO severity requirement: Plaque psoriasis requires psoriasis covering ≥3% BSA or psoriatic lesions affecting hands/feet/genital/scalp/face for initial coverage>=3% BSA or specific locations

    Document BSA or sensitive site involvement

    Prescriber restrictions for PsA/PSO/CD/UC: Prescribe by or in consultation with appropriate specialist (dermatologist for PSO; rheumatologist for PSA; gastroenterologist for CD/UC) where specifiednone

    Specialist consultation required for some products

    CF therapy restriction: CFTR modulators: initial authorization requires pulmonologist/CF expert and no concurrent use with another CFTR modulator; renewal requires improvement in clinical status and no concurrent CFTR modulator usenone

    Applies to CF entries

    Inability to swallow exception: For specified oral suspensions/pellets: trial of capsule/capsule suspension form OR documentation of inability to swallow capsules required before approving alternative formulationnone

    E.g., Rozlytrek pellet/capsule rules

    Product-specific coverage summary

    Coverage determinations for listed products follow the stated coverage durations and indications

    VYLOY: Covered for FDA‑approved indications with coverage duration 12 months; Part B prerequisite: No

    See specific product entry for details

    HERNEXEOS: Covered for FDA‑approved indications with coverage duration 12 months; Part B prerequisite: No
    ZURZUVAE ORAL CAPSULE (20/25/30 MG): Covered for FDA‑approved indications with coverage duration 14 days; Part B prerequisite: No

    Short course duration as listed

    Kineret (anakinra) is expressly excluded for the indication of COVID‑19 in hospitalized adults. Requests for Kineret to treat COVID‑19 in an inpatient setting will not meet coverage criteria and should be denied.

    CGRP inhibitor class policy: concurrent use of QULIPTA (and other CGRP inhibitors) with another CGRP inhibitor for migraine prevention is not permitted. For Aimovig and Ajovy the policy specifies prior authorization with an initial authorization typically 6 months and renewal 12 months, and renewal requires documented clinical benefit (reduction in migraine/headache frequency, severity, or duration). Any request proposing simultaneous preventive CGRP therapy will be considered non‑compliant with the concurrent‑use restriction and may be denied.

    Bosentan for pulmonary arterial hypertension is excluded from concurrent use with cyclosporine A or glyburide. In addition, initiation is contraindicated when liver transaminases (ALT/AST) are > 3× upper limit of normal or when bilirubin has increased by ≥ 2× ULN. Requests that show concurrent therapy with cyclosporine A or glyburide, or that document hepatic enzyme elevations above these thresholds, do not meet coverage criteria.

    Prior Authorization, Documentation & Denial Risks

    Prior Authorization

    TYMLOS — prior authorization; 24-month limit

    Prior authorization is required for TYMLOS. Coverage is limited to 24 months and the request must document that the patient has not received a total of 24 months cumulative parathyroid hormone therapy for osteoporosis.

    Prior Authorization

    HUMIRA family — PA with initial 6‑month (HS 12‑month) and 12‑month renewal

    Humira family products require prior authorization; initial authorizations are typically 6 months for most listed indications (12 months for hidradenitis suppurativa), and renewals are 12 months with documentation that the patient continues to benefit and no prohibited concurrent biologic/targeted small molecule use.

    Prior Authorization

    PA required for listed specialty drugs

    Prior authorization is required for the specialty products listed in this section (examples include Humira, Xeljanz, Orencia); coverage durations and product-specific clinical prerequisites are specified per product.

    Prior Authorization

    FASENRA — eosinophil ≥150 cells/mcL and PA

    Fasenra requires prior authorization for asthma and an initial blood eosinophil count ≥150 cells/mcL within the past 12 months; prescriber specialty and concurrent-therapy restrictions apply per indication.

    Prior Authorization

    General PA requirement — typical 12‑month duration

    Most specialty pharmacy products in this document require prior authorization; the common coverage duration is 12 months unless a product-specific exception is noted.

    Prior Authorization

    Mavenclad — limited-course authorization (48 weeks; cumulative limit)

    Mavenclad (cladribine) has a distinct authorization approach: initial coverage described as a 48‑week course with treatment limited by cumulative exposure (not to exceed two years total across courses).

    Documentation Required

    Specialist prescriber requirement and coverage durations

    Some products require prescription by or consultation with a specified specialist (examples: Huntington disease and tardive dyskinesia formulations), and those entries commonly set coverage durations (often 12 months; some 6 months) tied to specialist prescribing.

    Prior Authorization

    Dupilumab — indication‑specific PA and documentation

    Dupilumab prior authorization requires indication‑specific documentation (e.g., blood eosinophil 150–1500 cells/mcL for eosinophilic asthma, EoE confirmed by EGD with biopsy, AD extent ≥10% BSA or special‑site involvement) and appropriate specialist prescribing; renewal requires evidence of clinical improvement.

    Prior Authorization

    Balversa — PA; 12‑month coverage

    Balversa (erdafitinib) oral tablets require prior authorization; coverage duration is specified as 12 months and approvals apply to FDA‑approved indications.

    Prior Authorization

    CGRP inhibitors (Aimovig/Ajovy) — PA; initial 6‑month, renewal 12‑month

    Aimovig and Ajovy (CGRP inhibitors) require prior authorization: initial authorization typically 6 months with renewal at 12 months; concurrent use with other CGRP inhibitors for migraine prevention is not allowed and renewal requires documented reduction in migraine frequency/severity/duration.

    Prior Authorization

    VOWST — PA; 30‑day course and prior‑treatment rules

    VOWST requires prior authorization with a coverage period of 30 days; initial use requires prior antibiotic treatment for recurrent C. difficile infection or, if previously treated with VOWST, documentation of treatment failure and limits on prior courses.

    Prior Authorization

    Kerendia — PA; HF criteria and cardiology consult

    Kerendia (finerenone) prior authorization for heart‑failure indication requires NYHA class II–IV and LVEF ≥40% (not due to specified causes), prescriber by or in consultation with a cardiologist, and no concurrent mineralocorticoid receptor antagonist use.

    Prior Authorization

    HAE agents — PA; complement testing and specialty prescriber

    HAE agents require prior authorization with confirmatory complement testing to establish hereditary angioedema, prescription by or in consultation with an allergist/immunologist/hematologist, a 12‑month coverage period, and no concurrent use with medications for acute HAE attacks.

    Prior Authorization

    Imatinib / IMKELDI — PA; adjuvant GIST 36‑month duration; prior TKI exclusion

    Imatinib (and IMKELDI when used for patients unable to swallow generic tablets) requires prior authorization; adjuvant GIST treatment coverage is 36 months while other indications are 12 months, and Philadelphia chromosome‑positive CML coverage requires that the patient has not received prior TKI therapy.

    Prior Authorization

    Biologics (e.g., infliximab) — PA; step and concurrent‑use restrictions

    Infliximab and similar biologics require prior authorization with indication‑specific initial periods (typically 6 months) and 12‑month renewals, prescriber specialty restrictions, required prior trials of preferred agents for certain diagnoses, and prohibition on concurrent systemic biologic or targeted small‑molecule therapy.

    Billing Rule

    PA required for insulin supplies and select DME‑like items

    Prior authorization is required for the listed durable medical supplies (insulin syringes, pen needles, alcohol prep pads, sharps containers) and related injectables/pen kits; some items are covered under Part D only when used concurrently with insulin and have specific coverage durations.

    Prior Authorization

    CFTR modulators — PA; confirmed CFTR mutation and specialist prescriber

    Cystic fibrosis modulators require prior authorization with documentation of a confirmed CFTR mutation acceptable for the therapy, prescription by or in consultation with a pulmonologist or CF specialist, and initial coverage periods (commonly 6–12 months) with renewal based on clinical improvement.

    Prior Authorization

    NUCALA — PA; blood eosinophils ≥150 cells/mcL and specialist prescriber

    NUCALA (mepolizumab) prior authorization requires evidence of an eosinophilic phenotype (blood eosinophils ≥150 cells/mcL within the past 12 months for asthma), specialist prescriber, required background controller therapy, and renewal contingent on clinical response; concurrent anti‑IL‑5 biologics are not allowed.

    Prior Authorization

    Leuprolide — prescriber/duration notes; prostate cancer 12‑month

    Leuprolide products require indication‑consistent prior authorization; prostate cancer indications typically have 12‑month coverage and some formulations require payment‑determination notes.

    Prior Authorization

    Topical lidocaine — indication alignment and PA

    Topical lidocaine products require prior authorization and the indication must match listed pain conditions (post‑herpetic neuralgia, diabetic neuropathy, chronic back pain, osteoarthritis of knee/hip); billing/payment determination may vary with setting (Part B vs Part D).

    Prior Authorization

    Prior authorization — typical 12‑month coverage

    Prior authorization is required for many products and the common coverage duration for listed specialty agents is 12 months unless a product‑specific exception is specified.

    Prior Authorization

    OFEV — PA durations vary by ILD indication (SSC‑ILD 6 mo; IPF/PF‑ILD 12 mo)

    OFEV authorizations vary by indication: initial SSC‑ILD requests are typically 6 months while IPF and PF‑ILD initial requests are typically 12 months; renewal requests require documentation of clinical benefit and are usually 12 months.

    Prior Authorization

    Hypocalcemia/hypoparathyroidism — PA; endocrinology consult and calcitriol trial

    Hypocalcemia secondary to hypoparathyroidism requires prior authorization with prescriber being or consulting an endocrinologist, trial of or contraindication to calcitriol, exclusion for CSR‑mutation or acute post‑surgical hypoparathyroidism, and coverage duration of 12 months.

    Prior Authorization

    SIGNIFOR — PA; endocrinology prescriber; 6‑month initial

    SIGNIFOR for Cushing disease requires prior authorization with prescription by or in consultation with an endocrinologist; initial coverage is 6 months and renewal 12 months with evidence of continued improvement and tolerability.

    Prior Authorization

    CINQAIR — PA; eosinophils ≥150 cells/mcL and step trials

    CINQAIR for severe eosinophilic asthma requires prior authorization: blood eosinophils ≥150 cells/mcL within past 12 months, prescribed by or in consultation with allergy/pulmonary specialist, concurrent ICS plus another maintenance med, trial of or contraindication to two preferred agents (Fasenra, Nucala, Dupixent), no concurrent disallowed biologics, and renewal requires clinical response.

    Prior Authorization

    NURTEC — PA; triptan trial and CGRP concurrent‑use prohibition

    NURTEC ODT requires prior authorization: initial 6 months (renewal 12 months), documentation of trial of or contraindication to one triptan for acute migraine, no concurrent use with other CGRP inhibitors for acute or preventive migraine, and renewal requires patient‑reported improvement or consistent effectiveness.

    Prior Authorization

    Pirfenidone (IPF) — PA; UIP on HRCT and FVC ≥50%

    Pirfenidone for IPF requires prior authorization with HRCT demonstrating a UIP pattern (or surgical lung biopsy plus HRCT), baseline predicted FVC ≥50%, pulmonologist prescribing or consultation, and renewal contingent on meaningful improvement or maintenance in annual rate of decline.

    Prior Authorization

    ADEMPAS — PA; RHC confirmation and concurrent‑use exclusions

    Adempas (riociguat) for PAH requires prior authorization with diagnosis confirmed by right‑heart catheterization (mean PAP >20 mmHg, PCWP ≤15 mmHg, PVR >2 Wood units), prescriber specialty (cardiology or pulmonology), 12‑month initial/renewal coverage, and strict concurrent‑therapy exclusions (nitrates, nitric oxide donors, PDE inhibitors).

    Prior Authorization

    Penicillamine — PA; indication‑specific trials and diagnostics

    Penicillamine prior authorization varies by indication: Wilson disease requires a Leipzig score ≥4 with hepatology/gastroenterology prescriber; RA requires trial of or contraindication to 3 months of one DMARD (methotrexate ≥20 mg/week if tried); cystinuria and other indications have specified diagnostic requirements and specialist prescribers.

    Prior Authorization

    PEGASYS — PA; specialist prescriber and 48‑week duration for hepatitis

    PEGASYS (interferon) for hepatitis B/C requires prior authorization with prescription by or in consultation with a gastroenterologist, infectious disease specialist, or hepatologist; coverage for hepatitis B/C listed as 48 weeks.

    Prior Authorization

    PAH/CTEPH agents — PA; RHC confirmation and specialist consult

    Initial and renewal authorizations for PAH and CTEPH agents require right‑heart catheterization confirmation with specified hemodynamics, prescriber being or consulting a cardiologist or pulmonologist, coverage typically 12 months, and concurrent‑therapy exclusions as listed.

    Prior Authorization

    Biologics (dermatology/rheumatology) — PA with step‑therapy and specialist prescriber

    For dermatology/rheumatology biologics, prior authorization requires prior trials of specified therapies or contraindications (step therapy), prescriber specialty consultation, and limits on concurrent systemic biologic or targeted small‑molecule use; initial durations commonly 6 months with renewals at 12 months.

    Prior Authorization

    HCV agents — PA; HCV RNA within 6 months and drug‑interaction check

    HCV direct‑acting antivirals require prior authorization with documentation of HCV RNA within the prior 6 months and application of AASLD/IDSA‑aligned guidance; screening for listed drug interactions and hepatic impairment exclusions is required.

    Prior Authorization

    VOSEVI — PA; HCV RNA within 6 months and interaction exclusions

    VOSEVI prior authorization requires HCV RNA documentation within the past 6 months, verification that the patient is not taking listed interacting medications, and adherence to AASLD/IDSA guidance; decompensated cirrhosis may require concurrent ribavirin unless ineligible.

    Prior Authorization

    NORDITROPIN FLEXPRO — PA; HCV RNA and endocrinology consult

    NORDITROPIN FLEXPRO prior authorization requires indication‑appropriate documentation and includes an HCV RNA requirement within the prior 6 months for certain product‑affected entries; prescriber is or consults an endocrinologist for growth‑hormone indications.

    Prior Authorization

    Growth hormone products — PA; endocrinology prescriber and indication documentation

    Growth‑hormone products require prior authorization with indication‑specific documentation (e.g., pediatric GHD, ISS, SGA, Turner, Prader‑Willi), specialist (endocrinologist) prescribing or consultation, and renewal evidence of improvement.

    Prior Authorization

    Actemra — PA; step trials and rheumatology prescriber requirement

    Actemra prior authorization requires specialist prescriber (rheumatologist) for RA/PJIA and relevant specialists for other indications; RA initial approval requires trial of or contraindication to two preferred agents and initial periods are typically 6 months with 12‑month renewals.

    Prior Authorization

    ACTEMRA — prescriber specialty and initial durations

    ACTEMRA entries require that initial prescriptions for RA/PJIA be by or in consultation with a rheumatologist and that initial coverage durations vary by indication (e.g., 6 months for RA/PJIA/SJIA/GCA).

    Prior Authorization

    XELJANZ — PA; specialist prescriber and 6‑month initial

    Xeljanz/Xeljanz XR requires prior authorization with initial prescriptions by or in consultation with the appropriate specialist depending on indication (e.g., rheumatologist for RA, gastroenterologist for UC); initial authorization is 6 months with renewal at 12 months.

    Prior Authorization

    RINVOQ — PA; specialist prescriber, objective criteria, 6‑month initial

    RINVOQ (upadacitinib) prior authorization requires specialist prescribing or consultation appropriate to indication, an initial 6‑month authorization, and indication‑specific objective criteria (e.g., NR‑axSpA requires elevated CRP or sacroiliitis on MRI; AD requires ≥10% BSA or special‑site involvement).

    Step Therapy

    Initial DMARD trial requirement — 3 months (methotrexate ≥20 mg/wk if tried)

    Initial authorization for many biologics in RA requires documentation of trial of or contraindication to a 3‑month course of one DMARD (if methotrexate tried, dose ≥20 mg/week or maximally tolerated), and this must be documented in the PA request.

    Prior Authorization

    Coverage duration — common initial 6‑month then 12‑month renewal pattern

    Initial coverage durations are commonly 6 months for many biologics (examples listed) with renewals typically 12 months; exceptions and product‑specific durations are noted per drug entry.

    Billing Rule

    Payment determination (Part B vs Part D) may be required

    Payment determination may be required to establish whether a product is covered under Medicare Part B versus Part D for certain listed drugs (verify Part B vs Part D applicability when submitting PA).

    Prior Authorization

    Prior authorization and coverage durations — follow product‑specific limits

    Prior authorization is required for the listed specialty products; coverage durations are specified per product (commonly 12 months; some exceptions such as Zurzuvae 14 days) and must not be exceeded without authorization change.

    Product Codes, Strengths and Identifiers

    Listed products (drug names)mixed
    ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MGALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
    ALUNBRIG ORAL TABLETS,DOSE PACKALUNBRIG ORAL TABLETS,DOSE PACK
    HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT, 3,000 UNITHAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT, 3,000 UNIT
    dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 240 mgdimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 240 mg
    VUMERITYVUMERITY
    MODEYSOMODEYSO
    JEMPERLIJEMPERLI
    Product strengthsNDC
    ALVAIZALVAIZ (product listing)
    ELREXFIO (strengths noted in product entry)ELREXFIO vial/solution strengths referenced in product entry
    Product strengths and formulationsNDC
    ROZLYTREK CAPSULES / ORAL SUSPENSION / ORAL PELLETSRozlytrek capsule and pellet formulations and oral suspension option referenced (capsule-to-suspension trial required before pellets)
    XTANDI ORAL CAPSULE / ORAL TABLET 40 MG, 80 MGXTANDI listed as oral capsule/tablet strengths 40 mg, 80 mg
    Product strengthsNDC
    HEMOGLOBIN THRESHOLD CATEGORIESRetacrit hemoglobin-based indication thresholds referenced (e.g., <10 g/dL; surgery <13 g/dL)
    Product list (descriptive SKUs/names)mixed
    MONOJECT INSUL SYR U100MONOJECT INSUL SYR U100 (example syringe SKUs listed)
    LITE TOUCH PEN NEEDLE 31GLITE TOUCH pen needles and multiple syringe SKUs listed
    NOVOFINE / NANO PEN NEEDLESNOVOFINE, NANO and other pen needle product SKUs listed
    ASSORTED INSULIN SYRINGES AND ALCOHOL PREP PADSExtensive list of insulin syringes, pen needles, alcohol prep pads, and related items
    Listed product identifiers (examples)mixed
    UPTRAVI ORAL TABLET 200 MCG, 400 MCG, 600 MCG, 800 MCG, 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCGUPTRAVI oral tablet strengths listed
    UPTRAVI INTRAVENOUSUPTRAVI intravenous formulation listed
    HCV agentsmixedCovered
    EPCLUSA ORAL TABLET / ORAL PELLETSEPCLUSA (sofosbuvir/velpatasvir) oral tablet / oral pellets formulation
    VOSEVIVOSEVI (sofosbuvir/velpatasvir/voxilaprevir)
    Products listed (partial)mixed
    No codes listed
    Products listed (by name)mixed
    XELJANZXELJANZ (tofacitinib)
    XELJANZ XRXELJANZ XR
    Products listed (by name)mixed
    RINVOQRINVOQ (upadacitinib)
    RINVOQ LQRINVOQ LQ
    Products listed (by name)mixed
    ACTEMRAACTEMRA (tocilizumab) including ACTPEN
    TYENNETYENNE (tocilizumab biosimilar) including autoinjector
    Products listed (by name)mixed
    STELARASTELARA (ustekinumab)
    Oncology & biologic products listedmixed
    LOQTORZILOQTORZI
    OJEMDAOJEMDA (oral formulations)
    MEKINISTMEKINIST (trametinib) oral
    OGIVRIOGIVRI (biosimilar trastuzumab)

    Clinical Thresholds & Quick Values

    ARIKAYCE sputum culture threshold
    First renewalAt least 1 negative MAC sputum culture by 6 months of ARIKAYCE treatment; documentation of symptomatic improvement
    Second and subsequent renewalsAt least 3 negative MAC sputum cultures by 12 months of ARIKAYCE treatment; documentation of symptomatic improvement
    Prescriber requirementPrescribed by or in consultation with a pulmonologist or infectious disease specialist
    Blood eosinophil level
    General blood eosinophil threshold>= 150 cells/mcL
    Evidence windowMeasured within the past 12 months for asthma/eosinophilic indications
    Use in multiple productsRequired for initial approval of agents such as FASENRA, NUCALA, CINQAIR when indicated
    Mean pulmonary artery pressure (PAP)
    Mean pulmonary artery pressure (PAP)> 20 mmHg
    Context of measurementMeasured at right heart catheterization to confirm PAH diagnosis
    Applies toAdult and pediatric PAH diagnostic hemodynamics (with pediatric PVR adjustment)
    Pulmonary capillary wedge pressure (PCWP)
    Pulmonary capillary wedge pressure (PCWP)<= 15 mmHg
    Measurement methodMeasured via right heart catheterization as part of PAH hemodynamic confirmation
    RoleUsed to distinguish pre-capillary PAH (PCWP ≤15 mmHg) from left-heart disease
    Pulmonary vascular resistance (PVR)
    Pulmonary vascular resistance (PVR)> 2 Wood units
    Pediatric thresholdFor ages 1–17, PVR threshold used is ≥3 Wood units
    Measured duringRight heart catheterization (calculated from hemodynamic measurements)
    Serum ferritin for transfusional iron overload
    Initial transfusional iron overload threshold> 1000 mcg/L (serum ferritin), confirmed by at least two values in the prior 3 months
    Required documentationTwo serum ferritin values within the previous three months supporting the threshold
    PrescriberPrescribed by or in consultation with a hematologist or hematologist/oncologist
    Serum ferritin renewal threshold (transfusional)
    Renewal ferritin threshold (transfusional)> 500 mcg/L (serum ferritin), confirmed by at least two values in the prior 3 months
    DocumentationTwo recent serum ferritin values in prior three months required for renewal assessment
    ContextApplies to ongoing deferasirox therapy for transfusion-related iron overload
    Serum ferritin for NTDT initial
    NTDT initial ferritin threshold> 300 mcg/L (serum ferritin), confirmed by at least two values in the prior 3 months
    Additional requirementLiver iron concentration (LIC) criteria may apply (e.g., LIC ≥5 mg Fe/g dry weight) as noted
    PrescriberPrescribed by or in consultation with a hematologist or hematologist/oncologist
    Castrate testosterone threshold
    Castrate testosterone threshold< 50 ng/dL
    Use caseRequired documentation for androgen‑deprivation context (e.g., certain prostate cancer therapies) via bilateral orchiectomy or lab confirmation
    EvidenceTwo measures or documentation of orchiectomy/ongoing GnRH analog therapy used to establish castrate state as applicable
    Orthostatic hypotension BP change (droxidopa)
    Orthostatic BP change defining NOH>=20 mmHg systolic OR >=10 mmHg diastolic drop within 3 minutes of standing from sitting
    Required baseline measurementsBP while sitting and within 3 minutes of standing documented at baseline
    PrescriberPrescribed by or in consultation with a neurologist or cardiologist
    Eosinophil count for eosinophilic asthma
    Eosinophil count for eosinophilic asthma150 to 1500 cells/mcL within the past 12 months
    ContextUsed to identify eosinophilic asthma phenotype for biologics (e.g., dupilumab, mepolizumab) eligibility
    Measurement windowMost policies accept a recorded value within the prior 12 months
    Hemoglobin thresholds for EPO agents
    Hemoglobin threshold (general indications)Less than 10 g/dL for CKD, chemotherapy-related anemia, or zidovudine-associated anemia
    Surgery thresholdFor elective non-cardiac, non-vascular surgery: hemoglobin <13 g/dL
    Renewal considerationRenewal requires maintained hemoglobin responses or dose reductions/interruptions per indication guidance
    VYALEV levodopa requirement
    VY ALEV levodopa requirementCurrent regimen includes at least 400 mg/day of levodopa and average off time of ≥2.5 hours/day over 3 consecutive days (minimum 2 hours each day)
    PrescriberPrescribed by or in consultation with a neurologist for Parkinson disease indications
    RenewalRenewal requires improvement in motor symptoms while on therapy
    Opioid tolerance threshold
    Opioid tolerance definitionPrevious use equivalent to 60 mg oral morphine/day (or listed equianalgesic doses)
    Use caseApplies to coverage of morphine concentrate for patients with difficulty swallowing or in hospice/palliative care
    Coverage durationOpioid-tolerant use: 12 months; hospice/palliative/end‑of‑life: lifetime
    Blood eosinophil count (NUCALA)
    Blood eosinophil count (NUCALA)>= 150 cells/mcL within the past 12 months for asthma indication
    PrescriberPrescribed by or in consultation with a pulmonary or allergy specialist for asthma indication
    Concurrent therapy restrictionNo concurrent use with XOLAIR, DUPIXENT, TEZSPIRE, or other anti‑IL5 biologics for asthma
    Obstructive HCM LVOT gradient
    Obstructive HCM LVOT gradient threshold>= 50 mmHg
    PrescriberPrescribed by or in consultation with a cardiologist for obstructive HCM indications
    Prior therapyTrial of or contraindication to a beta‑blocker or non‑dihydropyridine calcium channel blocker required before some therapies
    Baseline FVC % predicted
    Baseline FVC % predictedIPF ≥50%; SSC-ILD ≥40%; PF-ILD ≥45%
    Imaging requirementHRCT demonstrating UIP pattern (or surgical lung biopsy + HRCT) required for IPF prior to antifibrotic therapy
    PrescriberPrescription by or in consultation with a pulmonologist (or rheumatologist for SSC-ILD) is required
    Total IgE serum level (XOLAIR)
    Total IgE serum level (XOLAIR)>= 30 IU/mL when indicated (e.g., allergic asthma or food allergy)
    Allergen-specific IgEWhen food allergy indication: specific IgE ≥6 kUA/L or positive skin prick or positive medically supervised oral food challenge
    PrescriberPrescribed by or in consultation with an allergist/immunologist when indicated
    Allergen-specific IgE for food allergy (XOLAIR)
    Allergen-specific IgE (food allergy - XOLAIR)>= 6 kUA/L OR positive skin prick test OR positive medically supervised oral food challenge to at least one food
    Concurrent therapyActive prescription for epinephrine auto-injector required for coverage of food allergy indication
    PrescriberPrescribed by or in consultation with an allergist or immunologist
    Blood eosinophil level (CINQAIR)
    CINQAIR blood eosinophil requirement≥ 150 cells/mcL within the past 12 months
    Additional asthma criteriaConcurrent medium/high‑dose ICS plus another maintenance med and prior exacerbation history or poor control per policy
    PrescriberPrescribed by or in consultation with an allergy or pulmonary specialist
    Predicted FVC (IPF)
    Predicted FVC requirement (IPF)≥ 50% at baseline
    Imaging requirementHRCT showing UIP pattern (or surgical lung biopsy + HRCT) required for IPF initial approval
    PrescriberPrescribed by or in consultation with a pulmonologist
    Right heart catheterization hemodynamics for PAH
    Right heart catheterization hemodynamics for PAHMean PAP > 20 mmHg; PCWP ≤ 15 mmHg; PVR > 2 Wood units
    Measurement contextObtained via right heart catheterization and required to confirm PAH diagnosis prior to PAH/CTEPH therapy
    Pediatric noteFor ages 1–17, pediatric PVR threshold differs (PVR ≥ 3 Wood units) though mean PAP and PCWP thresholds remain >20 and ≤15 mmHg respectively
    PAH hemodynamic thresholds (adult & pediatric)
    Adult PAH hemodynamic thresholdsMean PAP >20 mmHg; PCWP ≤15 mmHg; PVR >2 Wood units
    Pediatric thresholdPediatric (ages 1–17): PVR ≥3 Wood units
    UseRequired for initial and renewal authorizations for PAH agents
    HCV RNA recency requirement
    HCV RNA recency requirementHCV RNA level within the past 6 months required for DAA initiation
    Guideline alignmentCriteria applied consistent with current AASLD/IDSA guidance
    Drug interaction checkConfirm absence of listed contraindicated concomitant medications prior to DAA therapy
    Hemodynamic criteria for PAH
    Hemodynamic criteria for PAHMean PAP > 20 mmHg; PCWP ≤ 15 mmHg; PVR > 2 Wood units
    Confirmation methodMeasured by right heart catheterization prior to initiation of PAH-specific therapies
    Concurrent therapy exclusionsNo concurrent use with nitrates, nitric oxide donors, PDE inhibitors, or non-specific PDE inhibitors for many PAH agents
    Testosterone lab thresholds
    Total testosterone lab thresholdsTwo total serum testosterone measurements <300 ng/dL on separate occasions OR free testosterone <5 ng/dL
    Age-related screeningFor patients ≥40 years, PSA should be evaluated prior to initiation and at renewal
    Prescriber/coverageApplies to male hypogonadism confirmation for testosterone therapy prior authorization
    Atopic dermatitis extent (AD)
    Atopic dermatitis extent≥10% body surface area OR involvement of face/head/neck/hands/feet/groin/intertriginous areas
    PrescriberPrescribed by or in consultation with a dermatologist, allergist, or immunologist for AD indications
    UseApplies to dupilumab and other biologic approvals for AD severity assessment
    NR-axSpA objective evidence
    NR-axSpA objective evidenceElevated C‑reactive protein (CRP) OR sacroiliitis on MRI
    PurposeRequired to support coverage for non‑radiographic axial spondyloarthritis (NR‑axSpA)
    PrescriberPrescribed by or in consultation with a rheumatologist
    Methotrexate trial dose (step therapy)
    Methotrexate trial dose requirementIf methotrexate was tried, dose ≥20 mg per week or maximally tolerated dose required
    ContextRequired as part of DMARD trial documentation for RA prior to biologic or targeted therapy initiation
    DocumentationProvide trial duration and dose or documented intolerance/contraindication

    Initial Therapy / Medical Necessity Requirements

    Renewal / Continuation Requirements

    Step Therapy & Required Trials

    RequirementNotes / Evidence
    Trial of or contraindication to preferred agents (e.g., 3-month trial of one DMARD for RA) prior to approval of biologic/targeted agents
    Documentation must be provided (trial details or contraindication) and prescriber specialty requirements apply as indicated
    RequirementNotes / Evidence
    Trial of conventional systemic or topical therapies or phototherapy (e.g., methotrexate, cyclosporine, PUVA/UVB, topical corticosteroids) prior to biologic/targeted agent for psoriasis
    For moderate–severe plaque psoriasis: ≥3-month trial of an oral immunosuppressant or PUVA, or documented intolerance/contraindication; no concurrent use with another systemic biologic/targeted small molecule
    RequirementNotes / Evidence
    Trial of two preferred agents (exceptions: one preferred agent required for Crohn's disease) prior to many biologic approvals
    Exceptions: step-agent requirement may be waived for pregnancy, breastfeeding, or attempting pregnancy; documentation of trials or contraindications required
    RequirementNotes / Evidence
    Document trial of required prior therapy or provide documentation of contraindication
    Example: Acthar initial (except infantile spasms/MS) requires trial of IV corticosteroids or documentation of contraindication
    RequirementNotes / Evidence
    Trial of or contraindication to formulary alternatives is required for some products (e.g., formulary diclofenac products before certain topical solutions)
    Examples: eltrombopag oral suspension packets require prior trial of tablet formulation; elagolix requires trial of NSAID and progestin for endometriosis
    RequirementNotes / Evidence
    Trial of or contraindication to specified prior therapies required before biologic initiation for certain indications (e.g., IPF: trial of pirfenidone before OFEV; SSC-ILD: trial of or contraindication to Actemra SQ)
    Documentation of trial or contraindication must be included with PA request
    RequirementNotes / Evidence
    Must trial or have contraindication to two preferred agents before coverage for many rheumatologic indications (e.g., RA, PsA) prior to Actemra and similar biologics
    If methotrexate was tried, documentation should show dose ≥20 mg/week or maximally tolerated dose when applicable
    RequirementNotes / Evidence
    Trial of or contraindication to one generic octreotide injection required before initial approval of lanreotide (Somatuline) for acromegaly
    Prescriber must be or consult with an endocrinologist; initial coverage duration noted (acromegaly initial 3 months)
    RequirementNotes / Evidence
    Actimmune initial therapy must be prescribed by or in consultation with a specialist (e.g., hematologist, infectious disease specialist, immunologist for CGD)
    Initial coverage duration 6 months; renewal 12 months with demonstrated clinical benefit
    RequirementNotes / Evidence
    Attempt octreotide (generic) prior to lanreotide initiation for acromegaly unless contraindicated
    Documentation of trial or contraindication required; prescriber specialty: endocrinologist
    RequirementNotes / Evidence
    Use VITRAKVI capsule formulation prior to oral solution unless patient is unable to take capsules
    VITRAKVI oral solution approval requires trial of capsules or documentation of inability to swallow capsules
    RequirementNotes / Evidence
    Non-response or contraindication to first-line agents (NSAID and progestin-containing preparation) is required before initiation of GnRH agents (e.g., elagolix) for endometriosis
    Diagnosis confirmation (surgical/direct visualization or histopathology within 10 years) and OB/GYN prescriber requirements apply
    RequirementNotes / Evidence
    Document trial of or contraindication to preferred agent(s) where specified (e.g., OFEV IPF: trial of pirfenidone; Orfadin suspension: trial of preferred nitisinone tablets/capsules)
    Documentation must be included with PA requests; coverage durations and prescriber requirements vary by product
    RequirementNotes / Evidence
    CINQAIR initial requires trial of or contraindication to two preferred agents (FASENRA, NUCALA, DUPIXENT) before approval
    For ARCALYST (DIRA indication), trial of preferred agent KINERET is required in some cases
    RequirementNotes / Evidence
    Prior trials of specified formulary agents or classes required before approval (examples: oral ERAs, PDE‑5 inhibitors, phototherapy, DMARDs per indication)
    Step therapy specifics depend on indication; documentation of trials or contraindications required
    RequirementNotes / Evidence
    Trial of or contraindication to two preferred agents is required for RA prior to Actemra coverage
    Preferred agents include ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA; documentation required
    RequirementNotes / Evidence
    For certain PAH agents, patient must be on background PAH therapy for at least 3 months with at least two agents from different classes (oral ERA, PDE‑5 inhibitor, or oral sGC stimulator) or have documented contraindication/intolerance
    Diagnosis must be confirmed by right heart catheterization with specified hemodynamics; prescriber specialty required
    RequirementNotes / Evidence
    Prior trials or documented contraindications to specified prior therapies are required before approval for many products (examples: DMARDs, NSAIDs, oral immunosuppressants, phototherapy)
    Provider must supply documentation of trials, doses (e.g., methotrexate ≥20 mg/week if used), and prescriber specialty where indicated
    RequirementNotes / Evidence
    Trials of specified agents (oral immunosuppressants, DMARDs, NSAIDs) are required for psoriasis, psoriatic arthritis and related indications prior to biologic initiation
    Example: psoriasis requires ≥3-month trial of an oral immunosuppressant or PUVA or documented intolerance/contraindication; HF agents may require trial of preferred SGLT2 before Verquvo per product notes

    Quantity Limits & Course Restrictions

    VOWST — quantity / course limits
    VOWST quantity/course limitSingle course per authorization (coverage duration 30 days); repeat course allowed only with documented treatment failure and prior-course limits (no more than one prior course of at least 12 days and not more than 8 weeks prior)
    Initial-therapy prerequisiteCompletion of antibiotic treatment for recurrent CDI (at least 3 CDI episodes) for initial course
    Repeat-course conditionsRepeat requires documented treatment failure (CDI diarrhea within 8 weeks plus positive stool test) and prior-course timing constraints

    Site of Care & Payment Determination

    Billing Rule

    Infusion center — payment determination may be required (Part B vs Part D)

    Infusion‑center administered drugs may require payment determination to establish Medicare Part B versus Part D coverage; confirm site‑of‑care billing rules when submitting PA for infusion products.

    Billing Rule

    Mixed Part B/Part D designation — verify per product

    Some products have mixed Part B/Part D designation notes — confirm drug‑and‑use specific Part B prerequisite flags and include payment‑determination documentation when required.

    Biosimilar References & Requirements

    Billing Rule

    HERCEPTIN HYLECTA — trial of preferred biosimilars required

    For HERCEPTIN HYLECTA (trastuzumab reference products), PA may require trial of or contraindication to one of the preferred biosimilars (HERZUMA, OGIVRI, ONTRUZANT, TRAZIMERA) for adjuvant or metastatic breast cancer prior to approval.

    Policy Background

    This document provides prior authorization requirements and clinical prerequisites for a broad set of specialty pharmacy products used across oncology, rheumatology, dermatology, gastroenterology, pulmonary, and neurologic indications. Coverage is tied to FDA‑approved indications and typically requires documentation of indication‑specific diagnostics or biomarkers (for example, HCV RNA within the prior 6 months for HCV direct‑acting antivirals, right‑heart catheterization hemodynamics for pulmonary arterial hypertension, and complement testing to confirm hereditary angioedema).

    Common administrative expectations include specialist prescribing or consultation when specified, evidence of prior trials or contraindications to preferred or conventional therapies (step‑therapy), and demonstration of clinical benefit at renewal. Typical initial authorization periods are 6 months for many biologics and select agents, with renewals commonly set to 12 months, unless a drug‑specific duration is noted (for example, TYMLOS initial coverage is limited to 24 months).

    The policy emphasizes concurrent‑therapy exclusions and safety‑related contraindications that affect coverage decisions (examples: no concurrent use of multiple systemic biologics or targeted small molecules for the same indication; for PAH agents, no concurrent nitrates/PDE inhibitors and hemodynamic confirmation by right‑heart catheterization with mean PAP > 20 mmHg, PCWP ≤ 15 mmHg, and PVR > 2 Wood units).

    Providers should submit prior authorization requests with the required objective documentation (laboratory results, imaging, specialist consultation notes, and prior‑therapy trial documentation) as specified for each product to avoid delays or denials.

    Definitions and Abbreviations

    MAC lung disease renewal requirement
    MAC lung disease renewal requirementRenewal requires negative MAC sputum cultures per ARIKAYCE criteria and symptomatic improvement (first renewal: ≥1 negative culture by 6 months; subsequent: ≥3 negatives by 12 months)
    DocumentationProvide culture results and clinical improvement notes at renewal
    PrescriberTreatment managed by or in consultation with a pulmonologist or infectious disease specialist
    EGPA definition
    EGPA definitionEosinophilic granulomatosis with polyangiitis (EGPA) — requires no concurrent use with another systemic biologic or targeted small molecule; managed by specialist
    Clinical noteEGPA renewal expects symptom reduction or corticosteroid‑sparing effect without concurrent disallowed therapies
    PrescriberSpecialist involvement (allergy/pulmonology/rheumatology) recommended per indication
    PSO / PSA definition
    PSO / PSA definitionPsoriasis (PSO) and psoriatic arthritis (PSA): PSO moderate‑severe defined as ≥3% BSA or involvement of hands/feet/face/scalp/genital area; PSA managed with dermatology or rheumatology input
    Severity metricsSPGA and PASI scores referenced for mild/moderate distinctions (SPGA 2, PASI 2–9 for mild)
    PrescriberPSO: dermatologist; PSA: dermatologist or rheumatologist consultation advised
    HAE diagnostic testing
    HAE diagnostic testingConfirmatory complement testing: C1‑INH protein level, C4 protein, C1‑INH functional assay, or C1q
    Initial requirementRequired prior to initiation of HAE prophylactic or acute therapies
    PrescriberPrescribed by or in consultation with allergist, immunologist, hematologist, or pulmonologist as appropriate
    Chronic iron overload (transfusion-related)
    Chronic iron overload (transfusion-related)Defined as serum ferritin consistently >1000 mcg/L (at least two values in prior 3 months) for initial deferasirox approval
    PrescriberPrescribed by or in consultation with a hematologist/hematologist-oncologist
    Renewal criteriaRenewal threshold for transfusional iron overload: serum ferritin consistently >500 mcg/L (two values in prior 3 months)
    Opioid tolerant definition
    Opioid tolerant definitionPrevious use equivalent to 60 mg oral morphine/day (or listed equianalgesic doses such as 25 mcg/hr transdermal fentanyl, 30 mg oral oxycodone/day, etc.)
    Use caseDefines eligibility for morphine concentrate oral solution when patients have swallowing difficulties or are in hospice/palliative care
    Coverage durationOpioid‑tolerant use: 12 months; hospice/palliative/end‑of‑life: lifetime
    HAE definition
    HAE definitionHereditary angioedema (HAE): diagnosis must be confirmed by complement testing prior to initiation of HAE therapies
    Therapy constraintsNo concurrent use with other medications for acute HAE attacks when specified for prophylactic agents
    PrescriberPrescribed by or in consultation with appropriate specialty (allergist/immunologist/hematologist)
    Adjuvant GIST definition
    Adjuvant GIST definitionAdjuvant gastrointestinal stromal tumor (GIST) treatment: imatinib coverage duration 36 months for adjuvant setting
    Other indicationsAll other imatinib indications: coverage duration 12 months
    CML noteFor Ph+ CML, patient must not have received previous TKI therapy for certain coverage contexts
    Coverage Duration definition
    Coverage Duration definitionSpecified period the product will be covered (examples include LIFETIME, 12 MONTHS, 6 MONTHS) as noted per product
    Part D exceptionSome items (insulin administration supplies) are only covered under Part D when used concurrently with insulin
    DocumentationPA requests should reference the stated coverage duration for the specific product
    Right heart catheterization confirmation for PAH
    Right heart catheterization confirmation for PAHMean PAP >20 mmHg; PCWP ≤15 mmHg; PVR >2 Wood units — required to confirm PAH prior to PAH agent initiation
    Measurement methodObtained via right heart catheterization; documentation of these values required in PA requests
    PrescriberPrescribed by or in consultation with cardiologist or pulmonologist
    Eosinophilic asthma criterion for NUCALA
    Eosinophilic asthma criterion for NUCALABlood eosinophil count ≥150 cells/µL within the past 12 months
    Concurrent therapyPatient must be on appropriate background controller therapy (ICS + other maintenance med) per indication
    PrescriberPrescribed by or in consultation with allergy or pulmonary specialist
    UIP pattern (HRCT) definition
    UIP pattern (HRCT)Usual interstitial pneumonia pattern on HRCT required to support idiopathic pulmonary fibrosis diagnosis
    AlternativeSurgical lung biopsy plus HRCT acceptable when HRCT alone is inconclusive
    PrescriberPrescribed by or in consultation with a pulmonologist for IPF indications
    Succinylacetone (tyrosinemia biomarker)
    Succinylacetone (tyrosinemia biomarker)Elevated urinary or plasma succinylacetone confirms hereditary tyrosinemia type 1 (HT‑1) and supports nitisinone initiation
    Genetic confirmationFAH gene mutation also acceptable to confirm diagnosis
    Renewal metricRenewal requires decreased succinylacetone levels from baseline while on therapy
    Adult PAH hemodynamic criteria
    Adult PAH hemodynamic criteriaMean PAP >20 mmHg; PCWP ≤15 mmHg; PVR >2 Wood units
    Measurement methodRight heart catheterization required for confirmation
    PrescriberPrescribed by or in consultation with cardiology or pulmonology
    Pediatric PAH hemodynamic criteria
    Pediatric PAH hemodynamic criteriaAges 1–17: mean PAP >20 mmHg; PCWP ≤15 mmHg; PVR ≥3 Wood units
    DocumentationRight heart catheterization data specific to pediatric thresholds required for pediatric PAH approvals
    PrescriberPrescribed by or in consultation with pediatric cardiologist/pulmonologist as appropriate
    Locally advanced BCC baseline labs
    Baseline labs for locally advanced BCC agentBaseline serum creatine kinase (CK) and serum creatinine required prior to initiation
    ContextApplicable to specified agents treating locally advanced basal cell carcinoma
    DocumentationProvide baseline CK and creatinine values with PA request
    Male hypogonadism confirmation
    Male hypogonadism confirmationAt least two total serum testosterone levels <300 ng/dL on separate occasions OR free testosterone <5 ng/dL
    Age-related screeningFor patients ≥40 years, PSA evaluation required prior to initiation and at renewal
    Coverage durationTypical initial/renewal coverage: 12 months
    NR-axSpA definition
    NR-axSpA definitionNon‑radiographic axial spondyloarthritis requiring objective inflammatory evidence (elevated CRP or sacroiliitis on MRI)
    PrescriberPrescribed by or in consultation with a rheumatologist
    UseObjective evidence required for initial authorization decisions
    ADPKD definition
    ADPKD definitionAutosomal dominant polycystic kidney disease confirmed by imaging (CT, MRI, or ultrasound) required for initial tolvaptan approval
    PrescriberPrescribed by or in consultation with a nephrologist
    ExclusionInitial approval excludes patients with ESRD receiving dialysis

    Policy Revision History

    2025-12-01policy_effective_dateLatest

    Policy becomes effective for Elevate Medicare Choice (HMO D‑SNP) and Elevate Medicare Select (HMO); TYMLOS coverage duration specified as 24 months and prior‑therapy limit noted